Clinical trials: Psoriasis (PsO)
Plaque Psoriasis
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO who have not yet received any biologic therapy for any indication (other than insulin or hormones).
- Trial name
- NCT02134210
- Testing
- Etanercept, CHS-0214
- Where
- 100 sites in United States, Australia and 5 more
- Volunteers
- 521 people
- Sponsor
- Coherus Oncology, Inc.
Psoriasis (PsO), Obesity and Overweight
Effect of Semaglutide in Patients With Psoriasis and Obesity
Obesity is well known to be an important comorbidity of psoriasis. It gives rise to higher risk of psoriatic arthritis, more severe disease and also poorer response to biologics.
- Trial name
- SEMPSO (NCT06937060)
- Testing
- semaglutide
- Where
- Hong Kong
- Volunteers
- 14 people
- Sponsor
- The University of Hong Kong
Psoriasis (PsO), Psoriatic Arthritis (PsA)
A Clinical Trial of Antiplatelets in Psoriasis
The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more…
- Trial name
- NCT07744191
- Testing
- Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Psoriasis (PsO), Vitiligo Vulgaris
Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis
Primary objective: The primary objective is to evaluate in the general population the difference between emotional reactions associated with facial involvement by four major dermatologic diseases: psoriasis, atopic dermatitis…
- Conditions
- Psoriasis (PsO), Vitiligo Vulgaris, Atopic Dermatitis, Areata Alopecia
- Trial name
- STIGMADERM (NCT06801821)
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Psoriasis (PsO), Traditional Chinese Medicine (TCM)
Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine and Its Correlation With Laboratory Indicators
Psoriasis Vulgaris is a chronic, inflammatory, and immune-activated skin disease. It is the most common type of psoriasis, accounting for approximately 85-90% of all psoriasis patients.
- Conditions
- Psoriasis (PsO), Traditional Chinese Medicine (TCM), Diagnosis
- Trial name
- NCT07351448
- Testing
- No intervention
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Genital Psoriasis
A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)
The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to the summary of product characteristics (SmPC) and to…
- Trial name
- NCT06029257
- Testing
- Tildrakizumab
- Where
- Austria
- Volunteers
- 110 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
The study aims to evaluate the clinical efficacy of oral apremilast 30 mg BID compared with placebo in Chinese participants with moderate to severe PsO
- Trial name
- ESSENCE (NCT06122649)
- Testing
- apremilast
- Where
- 21 sites in China
- Volunteers
- 203 people
- Sponsor
- Amgen
Psoriasis, Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis.
- Trial name
- CIMPASI-2 (NCT02326272)
- Testing
- Certolizumab Pegol
- Where
- 23 sites in United States, Austria and 2 more
- Volunteers
- 227 people
- Sponsor
- UCB Biopharma S.P.R.L.
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE RADIANT (NCT03536884)
- Testing
- Bimekizumab, Secukinumab
- Where
- 77 sites in United States, Australia and 9 more
- Volunteers
- 743 people
- Sponsor
- UCB Biopharma SRL
Psoriasis (PsO), Psoriatic Arthritis (PsA)
Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis
Early diagnosis of psoriatic arthritis (PsA) requires close collaboration between dermatologists (as the skin manifestations of psoriatic disease in most cases precede the musculoskeletal manifestations) and rheumatologists (who…
- Trial name
- COMPOSITION (NCT07298265)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Charite University, Berlin, Germany
Psoriasis (PsO), PsA (Psoriatic Arthritis)
Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy
The goal of this research study is to better understand if there is an association between non-alcoholic fatty liver disease (NAFLD) and active psoriatic disease (PD), and to assess the effect of Guselkumab (a medication approved…
- Conditions
- Psoriasis (PsO), PsA (Psoriatic Arthritis), NAFLD (Nonalcoholic Fatty Liver Disease)
- Trial name
- EMERGE (NCT07255781)
- Testing
- Guselkumab Prefilled Syringe [Tremfya]
- Sponsor
- University of California, San Diego
Psoriasis (PsO), Psoriasis Arthritis
Molecular Inflammation Board at the Center for Personalized Medicine
Molecular Inflammation Board at the Center for Personalized Medicine
- Conditions
- Psoriasis (PsO), Psoriasis Arthritis, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Spondylarthropathies
- Trial name
- MEB@ZPM (NCT07132333)
- Testing
- Biologic Agent
- Where
- Germany
- Volunteers
- 3,000 people
- Sponsor
- University Hospital Tuebingen
Atopic Dermatitis (AD), Psoriasis (PsO)
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug.
- Trial name
- NCT06982352
- Testing
- LPX-TI641
- Where
- 3 sites in United States, Jordan
- Volunteers
- 48 people
- Sponsor
- LAPIX Therapeutics Inc.
Psoriasis, Psoriasis Arthritis
Psoriasis Comorbidities at Hospital Calderón Guardia
The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025.
- Conditions
- Psoriasis, Psoriasis Arthritis, Psoriasis (PsO), Psoriasis Patients
- Trial name
- NCT07448337
- Where
- Costa Rica
- Volunteers
- 350 people
- Sponsor
- Caja Costarricense de Seguro Social
Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS)
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
The goal of this observational study is to comprehensively profile six immune-mediated inflammatory diseases, including atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), cutaneous T-cell lymphoma…
- Conditions
- Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO), Atopic Dermatitis (AD)
- Trial name
- SKINERGY (NCT07021495)
- Where
- 8 sites in Netherlands
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Psoriasis
A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan
The purpose of this study is to understand current real-world treatment patterns and clinical outcomes, reasons for switching treatment, and participant characteristics using each systemic psoriasis treatment in Japan.
- Trial name
- NCT04826536
- Where
- Japan
- Volunteers
- 114 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis (PsO), Psoriatic Arthritis (PsA)
Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment
This was a retrospective observational study that relied on data extracted from patient chart review at the participating sites.
- Trial name
- NCT06666114
- Where
- Brazil
- Volunteers
- 232 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis (PsO), Psoriasis Arthritis
Definition of Novel Optoacoustic Biomarkers of Psoriasis and Psoriatic Arthritis
This study investigates changes in the skin and joints of people with psoriasis (PsO) and psoriatic arthritis (PsA) using two non-invasive imaging methods called raster-scan optoacoustic mesoscopy (RSOM) and multispectral…
- Trial name
- MOJMI (NCT07885345)
- Testing
- Raster-Scan Optoacoustic Mesoscopy, Multispectral Optoacoustic Tomography, Skin Biopsy and Skin Sample Collection
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School
Psoriasis
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
The purpose of this study is to further evaluate the safety of deucravacitinib treatment in Japanese patients with psoriasis in the real-world setting
- Trial name
- NCT06952465
- Testing
- Deucravacitinib, Any biologic treatment for psoriasis
- Where
- 2 sites in Japan
- Volunteers
- 2,000 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis (PsO), Periodontal Disease
Evaluation of TNF-α, IL-17A, and YKL-40 in GCF and Serum of Psoriasis Patients and Healthy Controls
Background: Psoriasis is a chronic inflammatory skin disease that affects 2-3% of the global population and is linked to immune dysregulation and systemic inflammation.
- Trial name
- NCT06897722
- Testing
- TNF-α analysis in GCF, IL-17A analysis in GCF, YKL-40 analysis in GCF
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Zhala Vatankha Sain